Fundraising FoxAhren Innovation Capital — 2018 Investments
1 investments dated 2018 · listed companies and verified rows first · show all
The company develops a 6-base sequencing platform (duet evoC) that simultaneously profiles methylation (5mC, 5hmC), genetic variants, and fragmentomics from a single cfDNA sample.
BiotechDeep TechHealthtechCambridge
Jason Mellad(Executive Officer, Director)inMartin Murphy(Director)Bobby Yerramilli-Rao(Co-founder)Somasundaram Subramaniam(Director)Timothy Rink(Director)Thomas Hulme(Director)
Board seatAlice Newcombe-EllisShankar Balasubramanian· per SEC Form D
Co-investorsThird Point VenturesGV (Google Ventures)New Science VenturesSequoia CapitalTemasekThird Point
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.